Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer

Gandhi, L.; Rodríguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Dómine, M.; Clingan, P.; Hochmair, M.; Powell, S.; Cheng, S.; Bischoff, H.; Peled, N.; Grossi, F.; Jennens, R.; Reck, M.; Hui, R.; Garon, E.; Boyer, M.; Rubio-Viqueira, B.; Novello, S.; Kurata, T.; Gray, J.; Vida, J.; Wei, Ziwen; Yang, Jing; Raftopoulos, H.; Pietanza, C.; Garassino, M.

doi:10.1056/NEJMoa1801005

Public

Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer

Shared by NobleBlocks on Apr 16, 2018 • 12:00 AM UTC

Authors:

L. Gandhi

D. Rodríguez-Abreu

S. Gadgeel

Abstract

BACKGROUND First‐line therapy for advanced non–small‐cell lung cancer (NSCLC) that lacks targetable mutations is platinum‐based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD‐L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!